Last reviewed · How we verify
Sulfadiazine (SULFADIAZINE)
Sulfadiazine is a sulfonamide antibacterial small molecule drug originally developed by Lederle and currently owned by Lilly. It targets the 5-hydroxytryptamine receptor 2A and has been FDA-approved since 1941 for various indications including burn wound infections, chorioretinitis, and toxoplasmosis. Sulfadiazine is available as a generic medication due to its off-patent status. It has a bioavailability of 90% and a half-life of 7.0 hours. As a sulfonamide antibacterial, it is effective against a range of bacterial infections.
At a glance
| Generic name | SULFADIAZINE |
|---|---|
| Sponsor | Eli Lilly |
| Drug class | Sulfonamide Antibacterial [EPC] |
| Target | 5-hydroxytryptamine receptor 2A |
| Modality | Small molecule |
| Therapeutic area | Immunology |
| Phase | FDA-approved |
| First approval | 1941 |
Approved indications
- Burn Wound Infections
- Chorioretinitis
- Congenital toxoplasmosis
- Encephalitis due to Toxoplasmosis
- Minor Bacterial Skin Infections
- Rheumatic Fever Prevention
- Skin ulcer
- Toxoplasmosis
- Toxoplasmosis associated with acquired immunodeficiency syndrome
- Ulcerative colitis
Common side effects
- Nausea
- Diarrhea
- Anorexia
- Abdominal pains
- Hepatitis
- Pancreatitis
- Stomatitis
- Headache
- Peripheral neuritis
- Mental depression
- Convulsions
- Ataxia
Drug interactions
- CYP2C9 Substrates
- warfarin
Key clinical trials
- Phase 2 Pilot Study of the Safety and Efficacy of Topical MW-III in Thermal Burns (PHASE2)
- Contact Activation of Coagulation in Newly Inserted Central Venous Catheters (NA)
- Microenvironment in Patients Undergoing Non-traumatic Amputation (NA)
- Silver Sulfadiazine With Hyaluronic Acid Versus Silver Sulfadiazine Alone in Partial-Thickness Burns (NA)
- Evaluation of the Effectiveness of a Topical Medical Device in Wound Healing and Symptom Relief in the Postoperative Period of Open Excisional Hemorrhoidectomy (The Emor Study) (PHASE4)
- Evaluation of a Management Strategy for Second-degree Fibrinous Burns Integrating a Poly-absorbent Dressing (NA)
- SWC for Treatment of Superficial Partial-Thickness Burns (NA)
- Effectiveness of KeraStat Gel for Improved Cosmesis of Partial Thickness Burns (NA)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| FDA label | Mechanism, indications, dosing, boxed warnings, drug interactions |
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- Sulfadiazine CI brief — competitive landscape report
- Sulfadiazine updates RSS · CI watch RSS
- Eli Lilly portfolio CI